Navigation Links
Genzyme Statement Regarding Results of FDA Advisory Committee Meeting on the Use of Phosphate Binders in Chronic Kidney Disease
Date:10/16/2007

has grown from a small start-up to a diversified enterprise with more than 9,500 employees in locations spanning the globe and 2006 revenues of $3.2 billion. In 2007, Genzyme was chosen to receive the National Medal of Technology, the highest honor awarded by the President of the United States for technological innovation. In 2006 and 2007, Genzyme was selected by FORTUNE as one of the "100 Best Companies to Work for" in the United States.

With many established products and services helping patients in nearly 90 countries, Genzyme is a leader in the effort to develop and apply the most advanced technologies in the life sciences. The company's products and services are focused on rare inherited disorders, kidney disease, orthopaedics, cancer, transplant, and diagnostic testing. Genzyme's commitment to innovation continues today with a substantial development program focused on these fields, as well as immune disease, infectious disease, and other areas of unmet medical need.

This press release contains forward-looking statements, including Genzyme's expectations regarding the timing for FDA action on its NDA seeking approval for the use of Renvela in dialysis patients, its plans to pursue approval of Renvela for treatment of CKD patients who are not on dialysis in the US and for dialysis and pre-dialysis patients globally, including expected filings in Europe and Latin America in 2008, and its clinical study plans. These statements are subject to risks and uncertainties that could cause actual results to differ materially from those projected in these forward- looking statements. These risks and uncertainties include, among others, the possibility that the FDA action with respect to the Renvela NDA is not favorable or is delayed, the possibility that Genzyme's plans for Renvela use in pre-dialysis patients will not be successful, and the possibility that regulatory authorities outside the US do not grant marketing authorization for the use of Renvela in
'/>"/>

SOURCE Genzyme
Copyright©2007 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2 3

Related medicine news :

1. Genzyme Announces First Phase III Study of Tolevamer in Diarrhea Patients
2. Fresh warnings to doctors regarding abortion pill
3. Researchers Present Data Regarding The Efficiency Of Herbs
4. Will anxiety regarding fertility treatment affect the chances of conception?
5. Changing Trends Regarding Insurance Cover For Weight Reduction Surgery
6. Indian Government warns Gujarat regarding possibility of bird flu
7. Leeches Provide Clues Regarding The Prevention Of Heart Disease
8. AIDS control requires co-coordinated move regarding safe sexual practices
9. Legal Action against Authority Regarding Outbreak of Legionnaires’ Diseas
10. Mixed Opinion Regarding Common Medical And Engineering Entrance Test
11. Adolescents Influenced By Maternal Attitude Regarding Weight Control
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/29/2008)... WASHINGTON, Aug. 29 /PRNewswire-USNewswire/ -- Th...onsistent procedures to allow the public to,see ex...ished today in the,Federal Register http://edocke...will ensure that the best and latest available evi... risk assessments for health,standards regulating ...
(Date:8/29/2008)...iation may have caused chromosomal change that rai... FRIDAY, Aug. 29 (HealthDay News) -- Some Japanese...in Hiroshima and Nagasaki experienced key genetic ...of thyroid cancer, new research indicates. , Pa...o a particular genetic mutation involving the so-c...
(Date:8/29/2008)... LEEDS, England, August 29 /PRNewswire/ --, - MYA...ce for Recent,Big Brother Stars but the big Questi...as, mirrors all around and being on national,telev...ct on how you feel,about the way you look. For man... a reality. Upon leaving the house contestants may...
(Date:8/29/2008)... Dr. Milton Owens and the Co... Southern California to provide protection for cas...on, and the Hispanic community is benefiting. , ...ust 29, 2008 -- Dr. Milton Owens and the Coastal C...rn California to provide protection for cash payin...
Breaking Medicine News(10 mins):Health News:Notice of Proposed Rulemaking on U.S. Department of Labor's Risk Assessment Procedures Published in Federal Register 2Health News:Some Hiroshima Survivors at Thyroid Cancer Risk 2Health News:Some Hiroshima Survivors at Thyroid Cancer Risk 3Health News:MYA Makes Big Brother Stars Amazing! 2Health News:MYA Makes Big Brother Stars Amazing! 3Health News:Coastal Center for Obesity Offers Hispanics Weight Loss Surgery with a Warranty 2
...result of the bird flu outbreak in the country. Th...ndustry to a very large extent//. Both the Governm...r citizens not to make tourist visits to Turkey. T...tourists. The outbreak in the country has badly af...
...ple suffering from stress and other related sympto...Westminster studied the stress levels // of 28 par...The researcher tells us that saliva cortisol level...one’s stress level. The participant’s saliva cort...
...ombining the two does wonders. In the same vein Ma... (MOH) China has announced that they // will pub...n. In his clarification and statement, "Last year,...AIDS) and the World Health Organization (WHO) join...
...na State University have successfully produced Pla...were able to produce vaccines from bioengineered /...nea pigs which were exposed to pneumonic plague ba...trial of the new vaccine in human to study the eff...
Other Medicine News:Health News:Tobacco plant based Vaccine against Plague 2
(Date:8/26/2008)...e/ -- Omeros Corporation today announced the,publi... investigating,OMS103HP in arthroscopic anterior c...103HP is an investigational drug product that is a...signed to improve postoperative,knee function and ...ts an,earlier return to work. The article titled "...
(Date:8/25/2008)...n and Treatment Strategies--, PHILADELPHIA, Aug. ...overed gene mutations that are the main cause of t...blastoma. In addition, the researchers found,that ...-risk forms of,non-inherited neuroblastoma, the mo...nables us to offer the first genetic tests to fami...
(Date:8/25/2008)... calls it a ,miracle, LATHAM, N.Y., Aug. 25 /PRN...ided Radiation Therapy program at Community Care P... patients using RapidArc(TM),radiotherapy technolo...dvancement that delivers a highly-precise image-gu...tment in two minutes or less., RapidArc treatment...
(Date:8/25/2008)...etreatment and Japanese Development Studies ...mark, August 25 /- Genmab h...umab in chronic lymphocytic,leukemia and non-Hodgk...oday plans to begin four studies of,ofatumumab in ...non-Hodgkin,s lymphoma (NHL) this year., "Genmab ...
Breaking Medicine Technology:Omeros Announces Publication of Clinical Results for OMS103HP in Arthroscopy: The Journal of Arthroscopic and Related Surgery 2Gene That Causes Childhood Cancer Neuroblastoma Is Found 2Gene That Causes Childhood Cancer Neuroblastoma Is Found 3Gene That Causes Childhood Cancer Neuroblastoma Is Found 4Image Guided Radiation Therapy in Latham, NY. Now Fighting Cancer Using Fast and Precise RapidArc(TM) Radiotherapy Technology 2Image Guided Radiation Therapy in Latham, NY. Now Fighting Cancer Using Fast and Precise RapidArc(TM) Radiotherapy Technology 3Genmab Announces Upcoming Ofatumumab Studies 2Genmab Announces Upcoming Ofatumumab Studies 3Genmab Announces Upcoming Ofatumumab Studies 4Thermage and Reliant Technologies to Join Forces 23310 1Thermage and Reliant Technologies to Join Forces 23310 2Thermage and Reliant Technologies to Join Forces 23310 3Thermage and Reliant Technologies to Join Forces 23310 4Thermage and Reliant Technologies to Join Forces 23310 5Thermage and Reliant Technologies to Join Forces 23310 6Thermage and Reliant Technologies to Join Forces 23310 7Angiotech to Establish Separate Operating and Royalty Businesses 6386 1Angiotech to Establish Separate Operating and Royalty Businesses 6386 2Angiotech to Establish Separate Operating and Royalty Businesses 6386 3Angiotech to Establish Separate Operating and Royalty Businesses 6386 4Angiotech to Establish Separate Operating and Royalty Businesses 6386 5Angiotech to Establish Separate Operating and Royalty Businesses 6386 6Angiotech to Establish Separate Operating and Royalty Businesses 6386 7Angiotech to Establish Separate Operating and Royalty Businesses 6386 8Angiotech to Establish Separate Operating and Royalty Businesses 6386 9Angiotech to Establish Separate Operating and Royalty Businesses 6386 10Angiotech to Establish Separate Operating and Royalty Businesses 6386 11Angiotech to Establish Separate Operating and Royalty Businesses 6386 12Angiotech to Establish Separate Operating and Royalty Businesses 6386 13Angiotech to Establish Separate Operating and Royalty Businesses 6386 14Edison Pharmaceuticals Receives Commendation From the City of San Jose 6382 1Edison Pharmaceuticals Receives Commendation From the City of San Jose 6382 2Newborn vitamin A reduces infant mortality 3904 1Newborn vitamin A reduces infant mortality 3904 2
...(CCNMatthews - June 14, 2007) - Ambrilia,Biopharma...oping,novel small molecules and peptides to treat ...neral and Special Meeting today, during,which the ...,integrase inhibitors and recent developments were...hairman of the Board, Mr. Frederic,Porte, and a pr...
...atient Trial Show Those Treated with Lumiracoxib,E...ressure Compared,to Ibuprofen, EAST HANOVER, N.J.,...arthritis who also have controlled hypertension ex... pressure when treated with,the investigational se...slight increase in those taking ibuprofen, a commo...
Other Medicine Technology:Ambrilia Highlights Encouraging Data for its HIV Integrase,Inhibitor Program and Recent Developments at Annual Meeting 2Ambrilia Highlights Encouraging Data for its HIV Integrase,Inhibitor Program and Recent Developments at Annual Meeting 3Ambrilia Highlights Encouraging Data for its HIV Integrase,Inhibitor Program and Recent Developments at Annual Meeting 4Lumiracoxib Study Showed Significantly Less Impact on Blood,Pressure Than Ibuprofen in Osteoarthritis Patients with Controlled,Hypertension 2Lumiracoxib Study Showed Significantly Less Impact on Blood,Pressure Than Ibuprofen in Osteoarthritis Patients with Controlled,Hypertension 3Lumiracoxib Study Showed Significantly Less Impact on Blood,Pressure Than Ibuprofen in Osteoarthritis Patients with Controlled,Hypertension 4Lumiracoxib Study Showed Significantly Less Impact on Blood,Pressure Than Ibuprofen in Osteoarthritis Patients with Controlled,Hypertension 5
...nse Webster is the source for a complete line of d...mapping - all with the quality, reliability and pr...eader in catheter technology. All of our coronary ...tructed to help minimize the frustration and exces...
A-Focus I & II Catheters. A-Focus steerable atrial mapping catheter. Available in 10, 12, 14 and 20 electrode configurations. (Shown with 14 electrodes).
Mennen Medical offers patient monitoring products for hospital based settings requiring high acuity and medium acuity monitoring. The Envoy patient monitor is Mennens premier monitoring product. The
...IS PhysioLog Hemodynamic Monitoring and Data Manag...m for the cath lab, integrating complete functiona...m analysis , Data collection , Inventory contr... , Procedural reporting ,Data collection ...
Medicine Products: